NCT06616584
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06616584
Title Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SWOG Cancer Research Network
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.